High-risk patients with heart failure had an over 40 percent lower risk of hospitalization or death after initiating weight loss drugs semaglutide or tirzepatide compared to placebo by proxy, according to a study out of Harvard-affiliated Mass General Brigham.

Specifically, researchers looked at heart failure with preserved ejection fraction (HFpEF), a condition where the heart’s ability to pump remains intact, yet the heart’s muscle has become so thick and stiff that the amount of blood being pumped doesn’t meet the body’s needs. This form of heart failure is especially common among people with obesity and Type 2 diabetes.

https://news.harvard.edu/gazette/story/2025/09/weight-loss-drugs-protect-heart-patients-study-suggests/